Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγ

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 2, 2016, Pages 138-147

  Chen, Jinbiao ^a   Wang, Wei ^b   Qi, Yanfei ^a   Kaczorowski, Dominik ^a   McCaughan, Geoffrey W ^a   Gamble, Jennifer R ^a   Don, Anthony S ^c   Gao, Xin ^b   Vadas, Mathew A ^a   Xia, Pu ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatocytes; Nonalcoholic fatty liver disease; PPAR ; Sphingolipids; Sphingosine kinase 1

Indexed keywords

BIOGENIC AMINE; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 2 PHOSPHATE; SPHINGOSINE 3 PHOSPHATE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; EDG3 PROTEIN, MOUSE; FAT INTAKE; LYSOPHOSPHOLIPID; MTOR PROTEIN, MOUSE; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; DOWN REGULATION; FATTY LIVER; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; FAT INTAKE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; LIPID DIET; MALE; METABOLISM; MOUSE MUTANT; OBESITY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DIET, HIGH-FAT; DIETARY FATS; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATOCYTES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOSPHINGOLIPID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOSINE; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84949501358     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2015.11.006     Document Type: Article

References (40)

1. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment. Pharmacol. Ther. 34 2011 274 285
2. C.D. Williams, J. Stengel, M.I. Asike, D.M. Torres, J. Shaw, M. Contreras, C.L. Landt, and S.A. Harrison Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 2011 124 131
3. E.M. Brunt Pathology of nonalcoholic fatty liver disease Nat. Rev. Gastroenterol. Hepatol. 7 2010 195 203
4. G. Musso, R. Gambino, and M. Cassader Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) Prog. Lipid Res. 48 2009 1 26
5. P. Tontonoz, and B.M. Spiegelman Fat and beyond: the diverse biology of PPARgamma Annu. Rev. Biochem. 77 2008 289 312
6. P. Pettinelli, and L.A. Videla Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction J. Clin. Endocrinol. Metab. 96 2011 1424 1430
7. K. Matsusue, M. Haluzik, G. Lambert, S.H. Yim, O. Gavrilova, J.M. Ward, B. Brewer Jr., M.L. Reitman, and F.J. Gonzalez Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes J. Clin. Invest. 111 2003 737 747
8. O. Gavrilova, M. Haluzik, K. Matsusue, J.J. Cutson, L. Johnson, K.R. Dietz, C.J. Nicol, C. Vinson, F.J. Gonzalez, and M.L. Reitman Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass J. Biol. Chem. 278 2003 34268 34276
9. M. Bedoucha, E. Atzpodien, and U.A. Boelsterli Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones J. Hepatol. 35 2001 17 23
10. J.P. Whitehead Diabetes: new conductors for the peroxisome proliferator-activated receptor gamma (PPARgamma) orchestra Int. J. Biochem. Cell Biol. 43 2011 1071 1074
11. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, and B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008 1017
12. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, T. Heller, E. Doo, M. Ghany, A. Premkumar, Y. Park, T.J. Liang, J.A. Yanovski, D.E. Kleiner, and J.H. Hoofnagle A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
13. M. Maceyka, K.B. Harikumar, S. Milstien, and S. Spiegel Sphingosine-1-phosphate signaling and its role in disease Trends Cell Biol. 22 2012 50 60
14. T. Hla, and A.J. Dannenberg Sphingolipid signaling in metabolic disorders Cell Metab. 16 2012 420 434
15. S. Spiegel, and S. Milstien Sphingosine-1-phosphate: an enigmatic signalling lipid Nat. Rev. Mol. Cell Biol. 4 2003 397 407
16. S.M. Pitson Regulation of sphingosine kinase and sphingolipid signaling Trends Biochem. Sci. 36 2011 97 107
17. T. Hashimoto, J. Igarashi, and H. Kosaka Sphingosine kinase is induced in mouse 3T3-L1 cells and promotes adipogenesis J. Lipid Res. 50 2009 602 610
18. W. Hu, J. Bielawski, F. Samad, A.H. Merrill Jr., and L.A. Cowart Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity J. Lipid Res. 50 2009 1852 1862
19. M. Kolak, J. Gertow, J. Westerbacka, S.A. Summers, J. Liska, A. Franco-Cereceda, M. Oresic, H. Yki-Jarvinen, P. Eriksson, and R.M. Fisher Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissue Lipids Health Dis. 11 2012 115
20. Y. Qi, J. Chen, A. Lay, A. Don, M. Vadas, and P. Xia Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice FASEB J. 27 2013 4294 4304
21. M. Bektas, M.L. Allende, B.G. Lee, W. Chen, M.J. Amar, A.T. Remaley, J.D. Saba, and R.L. Proia Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver J. Biol. Chem. 285 2010 10880 10889
22. Y. Osawa, E. Seki, Y. Kodama, A. Suetsugu, K. Miura, M. Adachi, H. Ito, Y. Shiratori, Y. Banno, J.M. Olefsky, M. Nagaki, H. Moriwaki, D.A. Brenner, and M. Seishima Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression FASEB J. 25 2011 1133 1144
23. G.M. Kowalski, J. Kloehn, M.L. Burch, A. Selathurai, S. Hamley, S.A. Bayol, S. Lamon, M.J. Watt, R.S. Lee-Young, M.J. McConville, and C.R. Bruce Overexpression of sphingosine kinase 1 in liver reduces triglyceride content in mice fed a low but not high-fat diet Biochim. Biophys. Acta 1851 2015 210 219
24. F. Feng, L. Wang, N. Albanese, A. Holmes, and P. Xia Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes Endocrinology 149 2008 1505 1513
25. O. Sukocheva, C. Wadham, A. Holmes, N. Albanese, E. Verrier, F. Feng, A. Bernal, C.K. Derian, A. Ullrich, M.A. Vadas, and P. Xia Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1 J. Cell Biol. 173 2006 301 310
26. R.K. Jaiswal, N. Jaiswal, S.P. Bruder, G. Mbalaviele, D.R. Marshak, and M.F. Pittenger Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase J. Biol. Chem. 275 2000 9645 9652
27. J.B. Chen, Y. Yu, J.L. Yang, D.A. Morgan, and W.R. Walsh BMP-7 and CBFA1 in allograft bone in vivo bone formation and the influence of gamma-irradiation J. Biomed. Mater. Res. A 80 2007 435 443
28. E.M. Brunt, D.E. Kleiner, L.A. Wilson, P. Belt, and B.A. Neuschwander-Tetri Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings Hepatology 53 2011 810 820
29. T. Yamazaki, S. Shiraishi, K. Kishimoto, S. Miura, and O. Ezaki An increase in liver PPARgamma2 is an initial event to induce fatty liver in response to a diet high in butter: PPARgamma2 knockdown improves fatty liver induced by high-saturated fat J. Nutr. Biochem. 22 2011 543 553
30. E. Moran-Salvador, M. Lopez-Parra, V. Garcia-Alonso, E. Titos, M. Martinez-Clemente, A. Gonzalez-Periz, C. Lopez-Vicario, Y. Barak, V. Arroyo, and J. Claria Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts FASEB J. 25 2011 2538 2550
31. K. Mendelson, T. Evans, and T. Hla Sphingosine 1-phosphate signalling Development 141 2014 5 9
32. M. Laplante, and D.M. Sabatini Regulation of mTORC1 and its impact on gene expression at a glance J. Cell Sci. 126 2013 1713 1719
33. B.A. Neuschwander-Tetri Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites Hepatology 52 2010 774 788
34. M.L. Allende, T. Sasaki, H. Kawai, A. Olivera, Y. Mi, G. van Echten-Deckert, R. Hajdu, M. Rosenbach, C.A. Keohane, S. Mandala, S. Spiegel, and R.L. Proia Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720 J. B. Chem. 279 2004 52487 52492
35. M.M. Ma, J.L. Chen, G.G. Wang, H. Wang, Y. Lu, J.F. Li, J. Yi, Y.J. Yuan, Q.W. Zhang, J. Mi, L. Wang, H.F. Duan, and C.T. Wu Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice Diabetologia 50 2007 891 900
36. C.R. Bruce, S. Risis, J.R. Babb, C. Yang, G.M. Kowalski, A. Selathurai, R.S. Lee-Young, J.M. Weir, K. Yoshioka, Y. Takuwa, P.J. Meikle, S.M. Pitson, and M.A. Febbraio Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice Diabetes 61 2012 3148 3155
37. D.F. Vatner, S.K. Majumdar, N. Kumashiro, M.C. Petersen, Y. Rahimi, A.K. Gattu, M. Bears, J.P. Camporez, G.W. Cline, M.J. Jurczak, V.T. Samuel, and G.I. Shulman Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids Proc. Natl. Acad. Sci. U. S. A. 112 2015 1143 1148
38. J.M. Peters, I. Rusyn, M.L. Rose, F.J. Gonzalez, and R.G. Thurman Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis Carcinogenesis 21 2000 823 826
39. R. Stienstra, F. Saudale, C. Duval, S. Keshtkar, J.E. Groener, N. van Rooijen, B. Staels, S. Kersten, and M. Muller Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity Hepatology 51 2010 511 522
40. G. Medina-Gomez, S.L. Gray, L. Yetukuri, K. Shimomura, S. Virtue, M. Campbell, R.K. Curtis, M. Jimenez-Linan, M. Blount, G.S. Yeo, M. Lopez, T. Seppanen-Laakso, F.M. Ashcroft, M. Oresic, and A. Vidal-Puig PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genet. 3 2007 e64